Login Register Cart 0
Generic placeholder image

Current Pediatric Reviews

Editor-in-Chief

ISSN (Print): 1573-3963
ISSN (Online): 1875-6336

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Hepatitis C Virus Exposure and Infection in the Perinatal Period

Author(s): Mine Varol, Ndeye Licka Dieye, Michael Zang, Deepali Handa, Shauna C. Zorich, Amy E. Millen and Oscar G. Gomez-Duarte*

Volume 19, Issue 1, 2023

Published on: 08 June, 2022

Page: [21 - 33] Pages: 13

DOI: 10.2174/1573396318666220417235358

Price: $65

Abstract

Background: Hepatitis C virus infection is a leading cause of blood-borne hepatitis disease worldwide. Hepatitis C is a silent liver disease that, without treatment, leads to late-onset complications, including chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma, in 10-40% of patients.

Objective: This study aimed to review the epidemiology, clinical features, diagnosis, treatment, and prevention of hepatitis C among perinatally exposed children.

Methods: Public databases, including MEDLINE and PubMed, and websites from the Centers for Disease Control and Prevention, the Food and Drug Administration, the World Health Organization, and the National Institutes of Health were searched for relevant articles published between 2006 and 2021.

Results: The prevalence of hepatitis C has increased among women of childbearing age in the United States and is associated with risk factors, such as intravenous drug use, health inequities, and low socioeconomic background. Infants born to hepatitis C virus-infected mothers have a 6% risk of vertical transmission, and among those infected, 75% will develop chronic hepatitis C and late complications. However, hepatitis C-exposed infants are frequently lost to follow-up, and those infected have delayed diagnosis and treatment and are at high risk for late-onset complications. Direct- acting antivirals and the establishment of effective treatment guidelines cure hepatitis C virus infections.

Conclusion: Hepatitis C predominantly affects underserved communities. Early screening of mothers and infants is critical for the diagnosis, treatment, and prevention of chronic infections and lateonset complications. New policies are needed to address hepatitis C health care inequities affecting mothers and infants in the United States.

Keywords: Hepatitis C, infants, perinatal, exposure, treatment, prevention, United States.

« Previous Next »
Graphical Abstract

[1]
The nobel prize in physiology or medicine. 2020. Available from: https://www.nobelprize.org/prizes/medicine/2020/summary/ (accessed Oct 8, 2021).
[2]
Blumberg BS, Alter HJ, Visnich S. A “NEW” antigen in leukemia sera. JAMA 1965; 191(7): 541-6.
[http://dx.doi.org/10.1001/jama.1965.03080070025007] [PMID: 14239025]
[3]
Alter HJ, Holland PV, Purcell RH, et al. Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Ann Intern Med 1972; 77(5): 691-9.
[http://dx.doi.org/10.7326/0003-4819-77-5-691] [PMID: 4628213]
[4]
Alter HJ, Purcell RH, Holland PV, Popper H. Transmissible agent in non-A, non-B hepatitis. Lancet 1978; 1(8062): 459-63.
[http://dx.doi.org/10.1016/S0140-6736(78)90131-9] [PMID: 76017]
[5]
Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244(4902): 359-62.
[http://dx.doi.org/10.1126/science.2523562] [PMID: 2523562]
[6]
Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM, Rice CM. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 1997; 277(5325): 570-4.
[http://dx.doi.org/10.1126/science.277.5325.570] [PMID: 9228008]
[7]
Galoppo M, Galoppo C. Management of hepatitis C virus infection in childhood. Ann Hepatol 2010; 9 (Suppl.): 98-102.
[http://dx.doi.org/10.1016/S1665-2681(19)31732-6] [PMID: 20714004]
[8]
Koneru A, Nelson N, Hariri S, et al. Increased hepatitis C virus (HCV) detection in women of childbearing age and potential risk for vertical transmission - United States and kentucky, 2011-2014. MMWR Morb Mortal Wkly Rep 2016; 65(28): 705-10.
[http://dx.doi.org/10.15585/mmwr.mm6528a2] [PMID: 27442053]
[9]
Zibbell JE, Iqbal K, Patel RC, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. MMWR Morb Mortal Wkly Rep 2015; 64(17): 453-8.
[PMID: 25950251]
[10]
Increase in hepatitis C infections linked to worsening opioid crisis.. 2017. Available from: https://www.cdc.gov/nchhstp/newsroom/2017/hepatitis-c-and-opioid-injection.html (accessed Sep 27, 2021)
[11]
Manos MM, Shvachko VA, Murphy RC, Arduino JM, Shire NJ. Distribution of hepatitis C virus genotypes in a diverse US integrated health care population. J Med Virol 2012; 84(11): 1744-50.
[http://dx.doi.org/10.1002/jmv.23399] [PMID: 22997077]
[12]
Nainan OV, Alter MJ, Kruszon-Moran D, et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 2006; 131(2): 478-84.
[http://dx.doi.org/10.1053/j.gastro.2006.06.007] [PMID: 16890602]
[13]
El Omari K, Iourin O, Kadlec J, et al. Unexpected structure for the N-terminal domain of hepatitis C virus envelope glycoprotein E1. Nat Commun 2014; 5(1): 4874.
[http://dx.doi.org/10.1038/ncomms5874] [PMID: 25224686]
[14]
Nayak A, Pattabiraman N, Fadra N, Goldman R, Kosakovsky Pond SL, Mazumder R. Structure-function analysis of hepatitis C virus envelope glycoproteins E1 and E2. J Biomol Struct Dyn 2015; 33(8): 1682-94.
[http://dx.doi.org/10.1080/07391102.2014.967300] [PMID: 25245635]
[15]
Catanese MT, Uryu K, Kopp M, et al. Ultrastructural analysis of hepatitis C virus particles. Proc Natl Acad Sci USA 2013; 110(23): 9505-10.
[http://dx.doi.org/10.1073/pnas.1307527110] [PMID: 23690609]
[16]
Adams RL, Pirakitikulr N, Pyle AM. Functional RNA structures throughout the Hepatitis C Virus genome. Curr Opin Virol 2017; 24: 79-86.
[http://dx.doi.org/10.1016/j.coviro.2017.04.007] [PMID: 28511116]
[17]
Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017; 2(3): 161-76.
[http://dx.doi.org/10.1016/S2468-1253(16)30181-9] [PMID: 28404132]
[18]
Rosenberg ES, Rosenthal EM, Hall EW, et al. Prevalence of hepatitis C virus infection in us states and the district of columbia, 2013 to 2016. JAMA Netw Open 2018; 1(8): e186371.
[http://dx.doi.org/10.1001/jamanetworkopen.2018.6371] [PMID: 30646319]
[19]
Hepatitis C. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (accessed Feb 28, 2021).
[20]
El-Ghitany EM, Farghaly AG. Geospatial epidemiology of hepatitis C infection in Egypt 2017 by governorate. Heliyon 2019; 5(8): e02249.
[http://dx.doi.org/10.1016/j.heliyon.2019.e02249] [PMID: 31463388]
[21]
Hofmeister MG, Rosenthal EM, Barker LK, et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016. Hepatology 2019; 69(3): 1020-31.
[http://dx.doi.org/10.1002/hep.30297] [PMID: 30398671]
[22]
Suryaprasad AG, White JZ, Xu F, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis 2014; 59(10): 1411-9.
[http://dx.doi.org/10.1093/cid/ciu643] [PMID: 25114031]
[23]
Ly KN, Jiles RB, Teshale EH, et al. Hepatitis C virus infection among reproductive-aged women and children in the United States, 2006 to 2014. Ann Intern Med 2017; 166(11): 775-82.
[http://dx.doi.org/10.7326/M16-2350] [PMID: 28492929]
[24]
Gowda C, Kennedy S, Glover C, Prasad MR, Wang L, Honegger JR. Enhanced identification of maternal hepatitis C virus infection using existing public health surveillance systems. Paediatr Perinat Epidemiol 2018; 32(4): 401-10.
[http://dx.doi.org/10.1111/ppe.12481] [PMID: 29972246]
[25]
Hepatitis C surveillance in the United States. 2019. Available from: https://www.cdc.gov/hepatitis/statistics/2019surveillance/HepC.htm (accessed Jul 6, 2021).
[26]
Campbell CA, Canary L, Smith N, Teshale E, Ryerson AB, Ward JW. State HCV incidence and policies related to HCV preventive and treatment services for persons who inject drugs - United States, 2015-2016. MMWR Morb Mortal Wkly Rep 2017; 66(18): 465-9.
[http://dx.doi.org/10.15585/mmwr.mm6618a2] [PMID: 28493854]
[27]
Hepatitis C surveillance in the United States. 2018. Available from: https://www.cdc.gov/hepatitis/statistics/2018surveillance/HepC.htm (accessed Feb 28, 2021).
[28]
Protopapas S, Murrison LB, Wexelblatt SL, Blackard JT, Hall ES. Addressing the disease burden of vertically acquired hepatitis C virus infection among opioid-exposed infants. Open Forum Infect Dis 2019; 6(12): ofz448.
[http://dx.doi.org/10.1093/ofid/ofz448] [PMID: 32128320]
[29]
Indolfi G, Bartolini E, Serranti D, Azzari C, Resti M. Hepatitis C in children co-infected with human immunodeficiency virus. J Pediatr Gastroenterol Nutr 2015; 61(4): 393-9.
[http://dx.doi.org/10.1097/MPG.0000000000000895] [PMID: 26147631]
[30]
Domínguez-Rodríguez S, Prieto L, Fernández McPhee C, et al. Madrid Cohort of HIV-infected motherinfant pairs. Perinatal HCV transmission rate in HIV/HCV coinfected women with access to art in Madrid, Spain. PLoS One 2020; 15(4): e0230109.
[http://dx.doi.org/10.1371/journal.pone.0230109] [PMID: 32271775]
[31]
Haight SC, Ko JY, Tong VT, Bohm MK, Callaghan WM. Opioid use disorder documented at delivery hospitalization - United States, 1999-2014. MMWR Morb Mortal Wkly Rep 2018; 67(31): 845-9.
[http://dx.doi.org/10.15585/mmwr.mm6731a1] [PMID: 30091969]
[32]
Moorman AC, de Perio MA, Goldschmidt R, et al. Testing and clinical management of health care personnel potentially exposed to hepatitis C virus - CDC guidance, United States, 2020. MMWR Recomm Rep 2020; 69(6): 1-8.
[http://dx.doi.org/10.15585/mmwr.rr6906a1] [PMID: 32701942]
[33]
Workowski KA, Bolan GA. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64(RR-03): 1-137.
[PMID: 26042815]
[34]
Njuguna HN, Stinson D, Montgomery P, et al. Hepatitis C virus potentially transmitted by opioid drug diversion from a nurse - Washington, August 2017-March 2018. MMWR Morb Mortal Wkly Rep 2019; 68(16): 374-6.
[http://dx.doi.org/10.15585/mmwr.mm6816a3] [PMID: 31022162]
[35]
Arnold S, Melville SK, Morehead B, Vaughan G, Moorman A, Crist MB. Notes from the Field: Hepatitis C transmission from inappropri-ate reuse of saline flush syringes for multiple patients in an acute care general hospital - Texas, 2015. MMWR Morb Mortal Wkly Rep 2017; 66(9): 258-60.
[http://dx.doi.org/10.15585/mmwr.mm6609a4] [PMID: 28278142]
[36]
Centers for Disease Control and Prevention (CDC). Transmission of hepatitis C virus through transplanted organs and tissue--Kentucky and Massachusetts, 2011. MMWR Morb Mortal Wkly Rep 2011; 60(50): 1697-700.
[PMID: 22189891]
[37]
Indolfi G, Azzari C, Resti M. Perinatal transmission of hepatitis C virus. J Pediatr 2013; 163(6): 1549-1552.e1.
[http://dx.doi.org/10.1016/j.jpeds.2013.06.077] [PMID: 23919905]
[38]
Mariné-Barjoan E, Berrébi A, Giordanengo V, et al. HCV/HIV co-infection, HCV viral load and mode of delivery: Risk factors for mother-to-child transmission of hepatitis C virus? AIDS 2007; 21(13): 1811-5.
[http://dx.doi.org/10.1097/QAD.0b013e3282703810] [PMID: 17690581]
[39]
Arshad M, El-Kamary SS, Jhaveri R, Hepatitis C. Hepatitis C virus infection during pregnancy and the newborn period--are they opportu-nities for treatment? J Viral Hepat 2011; 18(4): 229-36.
[http://dx.doi.org/10.1111/j.1365-2893.2010.01413.x] [PMID: 21392169]
[40]
Watts T, Stockman L, Martin J, Guilfoyle S, Vergeront JM. Increased risk for mother-to-infant transmission of hepatitis C virus among medicaid recipients - wisconsin, 2011-2015. MMWR Morb Mortal Wkly Rep 2017; 66(42): 1136-9.
[http://dx.doi.org/10.15585/mmwr.mm6642a3] [PMID: 29072864]
[41]
Jhaveri R, Swamy GK, Hepatitis C. Hepatitis C virus in pregnancy and early childhood: Current understanding and knowledge deficits. J Pediatric Infect Dis Soc 2014; 3 (Suppl. 1): S13-8.
[http://dx.doi.org/10.1093/jpids/piu045] [PMID: 25232471]
[42]
Apata IW, Averhoff F, Pitman J, et al. Centers for Disease Control and Prevention (CDC). Progress toward prevention of transfusion-transmitted hepatitis B and hepatitis C infection--sub-Saharan Africa, 2000-2011. MMWR Morb Mortal Wkly Rep 2014; 63(29): 613-9.
[PMID: 25055184]
[43]
Patrick SW, Bauer AM, Warren MD, Jones TF, Wester C, Hepatitis C. Hepatitis C virus infection among women giving birth - Tennessee and United States, 2009-2014. MMWR Morb Mortal Wkly Rep 2017; 66(18): 470-3.
[http://dx.doi.org/10.15585/mmwr.mm6618a3] [PMID: 28493860]
[44]
Centers for Disease Control and Prevention (CDC). Hepatitis C virus infection among adolescents and young adults: Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep 2011; 60(17): 537-41.
[PMID: 21544042]
[45]
Ko JY, Haight SC, Schillie SF, Bohm MK, Dietz PM. National trends in hepatitis C infection by opioid use disorder status among pregnant women at delivery hospitalization - United States, 2000-2015. MMWR Morb Mortal Wkly Rep 2019; 68(39): 833-8.
[http://dx.doi.org/10.15585/mmwr.mm6839a1] [PMID: 31581170]
[46]
Hughes BL, Page CM, Kuller JA. Society for Maternal-Fetal Medicine (SMFM). Electronic address: Pubs@smfm.org. Hepatitis C in preg-nancy: Screening, treatment, and management. Am J Obstet Gynecol 2017; 217(5): B2-B12.
[http://dx.doi.org/10.1016/j.ajog.2017.07.039] [PMID: 28782502]
[47]
Workowski KA, Berman SM. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep 2006; 55(RR-11): 1-94.
[48]
Workowski KA, Berman S. Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59(RR-12): 1-110.
[PMID: 21160459]
[49]
Centers for Disease Control and Prevention (CDC). Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men--New York City, 2005-2010. MMWR Morb Mortal Wkly Rep 2011; 60(28): 945-50.
[PMID: 21775948]
[50]
Apostolou A, Bartholomew ML, Greeley R, et al. Centers for Disease Control and Prevention (CDC). Transmission of hepatitis C virus associated with surgical procedures - New Jersey 2010 and Wisconsin 2011. MMWR Morb Mortal Wkly Rep 2015; 64(7): 165-70.
[PMID: 25719676]
[51]
Centers for Disease Control and Prevention (CDC). Investigation of viral hepatitis infections possibly associated with health-care delivery--New York City, 2008-2011. MMWR Morb Mortal Wkly Rep 2012; 61(19): 333-8.
[PMID: 22592271]
[52]
Leach M, Chapin S, Porges I, et al. Evaluation of risk factors for hepatitis C virus infection among philadelphia’s shelter-bound, homeless population: Data from a student-run hepatitis C virus screening initiative. Popul Health Manag 2021; 24(4): 448-53.
[http://dx.doi.org/10.1089/pop.2020.0143] [PMID: 33252303]
[53]
Ohringer AR, Serota DP, McLean RL, Stockman LJ, Watt JP. Disparities in risk perception and low harm reduction services awareness, access, and utilization among young people with newly reported hepatitis C infections in California, 2018. BMC Public Health 2021; 21(1): 1435.
[http://dx.doi.org/10.1186/s12889-021-11492-3] [PMID: 34289822]
[54]
Mateu-Gelabert P, Guarino H, Zibbell JE, et al. Prescription opioid injection among young people who inject drugs in New York City: A mixed-methods description and associations with hepatitis C virus infection and overdose. Harm Reduct J 2020; 17(1): 22.
[http://dx.doi.org/10.1186/s12954-020-00367-2] [PMID: 32228700]
[55]
Ahrens KA, Rossen LM, Burgess AR, Palmsten KK, Ziller EC. Rural-urban residence and maternal hepatitis C infection, U.S.: 2010-2018. Am J Prev Med 2021; 60(6): 820-30.
[http://dx.doi.org/10.1016/j.amepre.2020.12.020] [PMID: 33640230]
[56]
Razavi H, Elkhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013; 57(6): 2164-70.
[http://dx.doi.org/10.1002/hep.26218] [PMID: 23280550]
[57]
Wedemeyer H, Dore GJ, Ward JW. Estimates on HCV disease burden worldwide - filling the gaps. J Viral Hepat 2015; 22 (Suppl. 1): 1-5.
[http://dx.doi.org/10.1111/jvh.12371] [PMID: 25560838]
[58]
European Assocation for the Study of the Liver. LEASL clinical practice guidelines: Management of hepatitis C virus infection. J Hepatol 2011; (55): 245-64.
[59]
Prasad M, Saade GR, Sandoval G, et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Hepatitis C virus antibody screening in a cohort of pregnant women: Identifying seroprevalence and risk factors. Obstet Gynecol 2020; 135(4): 778-88.
[http://dx.doi.org/10.1097/AOG.0000000000003754] [PMID: 32168224]
[60]
Hoofnagle JH, Hepatitis C, Hepatitis C. The clinical spectrum of disease. Hepatology 1997; 26(3) (Suppl. 1): 15S-20S.
[http://dx.doi.org/10.1002/hep.510260703] [PMID: 9305658]
[61]
Piffer S, Mazza A, Dell’Anna L. Serological screening for hepatitis C during pregnancy: Seroprevalence and maternal and neonatal outcomes in 45,000 pregnant women. Eur J Obstet Gynecol Reprod Biol 2020; 254: 195-9.
[http://dx.doi.org/10.1016/j.ejogrb.2020.09.023] [PMID: 33017709]
[62]
Money D, Boucoiran I, Wagner E, et al. Obstetrical and neonatal outcomes among women infected with hepatitis C and their infants. J Obstet Gynaecol Can 2014; 36(9): 785-94.
[http://dx.doi.org/10.1016/S1701-2163(15)30480-1] [PMID: 25222357]
[63]
Salemi JL, Whiteman VE, August EM, Chandler K, Mbah AK, Salihu HM. Maternal hepatitis B and hepatitis C infection and neonatal neurological outcomes. J Viral Hepat 2014; 21(11): e144-53.
[http://dx.doi.org/10.1111/jvh.12250] [PMID: 24666386]
[64]
Mack CL, Gonzalez-Peralta RP, Gupta N, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr 2012; 54(6): 838-55.
[http://dx.doi.org/10.1097/MPG.0b013e318258328d] [PMID: 22487950]
[65]
Padhi S, Maharshi S, Gupta GK, Garg K, Nijhawan S. Efficacy and safety of direct acting antiviral therapy for chronic hepatitis C in thalassemic children. J Pediatr Hematol Oncol 2018; 40(7): 511-4.
[http://dx.doi.org/10.1097/MPH.0000000000001217] [PMID: 29771862]
[66]
Garazzino S, Calitri C, Versace A, et al. Natural history of vertically acquired HCV infection and associated autoimmune phenomena. Eur J Pediatr 2014; 173(8): 1025-31.
[http://dx.doi.org/10.1007/s00431-014-2286-6] [PMID: 24585099]
[67]
Resti M, Bortolotti F, Vajro P, Maggiore G. Committee of Hepatology of the Italian Society of Pediatric Gastroenterology and Hepatology. Guidelines for the screening and follow-up of infants born to anti-HCV positive mothers. Dig Liver Dis 2003; 35(7): 453-7.
[http://dx.doi.org/10.1016/S1590-8658(03)00217-2] [PMID: 12870728]
[68]
Owens DK, Davidson KW, Krist AH, et al. US Preventive Services Task Force. Screening for hepatitis C virus infection in adolescents and adults: US preventive services task force recommendation statement. JAMA 2020; 323(10): 970.
[http://dx.doi.org/10.1001/jama.2020.1123]
[69]
Chapman LE, Sullivent EE, Grohskopf LA, et al. Centers for Disease Control and Prevention (CDC). Recommendations for postexposure interventions to prevent infection with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus, and tetanus in persons wounded during bombings and other mass-casualty events United States, 2008: Recommendations of the centers for disease control and prevention (CDC). MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep 2008; 57(RR-6): 1-21.
[70]
Chappell CA, Hillier SL, Crowe D, et al. Hepatitis C virus screening among children exposed during pregnancy. Pediatrics 2018; 141(6): e20173273.
[http://dx.doi.org/10.1542/peds.2017-3273] [PMID: 29720535]
[71]
Flanigan CA, Leung SJ, Rowe KA, et al. Evaluation of the impact of mandating health care providers to offer hepatitis C virus screening to all persons born during 1945-1965 - New York, 2014. MMWR Morb Mortal Wkly Rep 2017; 66(38): 1023-6.
[http://dx.doi.org/10.15585/mmwr.mm6638a3] [PMID: 28957037]
[72]
Moorman AC, Drobenuic J, Kamili S. Prevalence of false-positive hepatitis C antibody results, National Health and Nutrition Examination Study (NHANES) 2007-2012. J Clin Virol 2017; 89: 1-4.
[http://dx.doi.org/10.1016/j.jcv.2017.01.007] [PMID: 28171829]
[73]
Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC recommendations for hepatitis C screening among adults - United States, 2020. MMWR Recomm Rep 2020; 69(2): 1-17.
[http://dx.doi.org/10.15585/mmwr.rr6902a1] [PMID: 32271723]
[74]
HCV in Pregnancy | HCV Guidance. Available from: https://www.hcvguidelines.org/unique-populations/pregnancy (accessed Jul 1, 2021).
[75]
Epstein RL, Sabharwal V, Wachman EM, et al. Perinatal transmission of hepatitis C virus: Defining the cascade of care. J Pediatr 2018; 203: 34-40.e1.
[http://dx.doi.org/10.1016/j.jpeds.2018.07.006] [PMID: 30170857]
[76]
Nasrullah M, Sergeenko D, Gvinjilia L, et al. The role of screening and treatment in national progress toward hepatitis C elimination - Georgia, 2015-2016. MMWR Morb Mortal Wkly Rep 2017; 66(29): 773-6.
[http://dx.doi.org/10.15585/mmwr.mm6629a2] [PMID: 28749925]
[77]
Elrazek A, Saab S, Foad M, et al. Ongoing transmission of HCV: Should cesarean section be justified? Data mining discovery. J Transl Int Med 2017; 5(1): 27-33.
[http://dx.doi.org/10.1515/jtim-2017-0001] [PMID: 28680836]
[78]
Kuncio DE, Newbern EC, Johnson CC, Viner KM. Failure to test and identify perinatally infected children born to hepatitis C virus-infected women. Clin Infect Dis 2016; 62(8): 980-5.
[http://dx.doi.org/10.1093/cid/ciw026] [PMID: 26797211]
[79]
HCV in Children | HCV Guidance. Available from: https://www.hcvguidelines.org/unique-populations/children (accessed Feb 28, 2021).
[80]
Centers for Disease Control and Prevention (CDC). Testing for HCV infection: An update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep 2013; 62(18): 362-5.
[PMID: 23657112]
[81]
Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up prevention and treatment towards the elimination of hepatitis C: A global mathematical model. Lancet 2019; 393(10178): 1319-29.
[http://dx.doi.org/10.1016/S0140-6736(18)32277-3] [PMID: 30704789]
[82]
Polywka S, Pembrey L, Tovo P-A, Newell M-L. Accuracy of HCV-RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection. J Med Virol 2006; 78(2): 305-10.
[http://dx.doi.org/10.1002/jmv.20540] [PMID: 16372293]
[83]
Kimberlin DW, Brady MT. Recommendations for Care of Children in Special Circumstances. Hepatitis C Red Book 2015.
[84]
Munier A, Marzouk D, Abravanel F, et al. Frequent transient hepatitis C viremia without seroconversion among healthcare workers in Cairo, Egypt. PLoS One 2013; 8(2): e57835.
[http://dx.doi.org/10.1371/journal.pone.0057835] [PMID: 23469082]
[85]
Alter MJ, Kuhnert WL, Finelli L. Centers for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for disease control and prevention. MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep 2003; 52(RR-3): 1-13.
[86]
Lee SR, Kardos KW, Schiff E, et al. Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. J Virol Methods 2011; 172(1-2): 27-31.
[http://dx.doi.org/10.1016/j.jviromet.2010.12.009] [PMID: 21182871]
[87]
Smith BD, Drobeniuc J, Jewett A, et al. Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus. J Infect Dis 2011; 204(6): 825-31.
[http://dx.doi.org/10.1093/infdis/jir422] [PMID: 21849279]
[88]
Kumar A, Rajput MK, Paliwal D, Yadav A, Chhabra R, Singh S. Genotyping & diagnostic methods for hepatitis C virus: A need of low-resource countries. Indian J Med Res 2018; 147(5): 445-55.
[http://dx.doi.org/10.4103/ijmr.IJMR_1850_16] [PMID: 30082568]
[89]
European Association for the Study of the Liver. Electronic address: Easloffice@easloffice.eu. EASL Recommendations on treatment of hepatitis C 2016. J Hepatol 2017; 66(1): 153-94.
[http://dx.doi.org/10.1016/j.jhep.2016.09.001] [PMID: 27667367]
[90]
Hullegie SJ. GeurtsvanKessel CH, van der Eijk AA, Ramakers C, Rijnders BJA. HCV antigen instead of RNA testing to diagnose acute HCV in patients treated in the Dutch Acute HCV in HIV Study. J Int AIDS Soc 2017; 20(1): 21621.
[http://dx.doi.org/10.7448/IAS.20.1.21621] [PMID: 28692208]
[91]
Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: A systematic review. JAMA 2007; 297(7): 724-32.
[http://dx.doi.org/10.1001/jama.297.7.724] [PMID: 17312292]
[92]
Pfaender S, Heyden J, Friesland M, et al. Inactivation of hepatitis C virus infectivity by human breast milk. J Infect Dis 2013; 208(12): 1943-52.
[http://dx.doi.org/10.1093/infdis/jit519] [PMID: 24068703]
[93]
Afdhal NH. Fibroscan (transient elastography) for the measurement of liver fibrosis. Gastroenterol Hepatol (N Y) 2012; 8(9): 605-7.
[PMID: 23483859]
[94]
Latif S, Kalam Q, Zuberi BF. Correlation between serum ferritin levels and liver stiffness measured by fibroscan in patients with chronic hepatitis C. Pak J Med Sci 2020; 36(3): 355-9.
[http://dx.doi.org/10.12669/pjms.36.3.1288] [PMID: 32292433]
[95]
Varchetta S, Mele D, D’Ambrosio R, et al. A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C. J Viral Hepat 2021; 28(10): 1443-51.
[http://dx.doi.org/10.1111/jvh.13570] [PMID: 34228858]
[96]
El-Guindi MA, Hepatitis C. Hepatitis C viral infection in children: Updated review. Pediatr Gastroenterol Hepatol Nutr 2016; 19(2): 83-95.
[http://dx.doi.org/10.5223/pghn.2016.19.2.83] [PMID: 27437184]
[97]
Chung RT, Ghany MG, Kim AY, et al. AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommen-dations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis 2018; 67(10): 1477-92.
[http://dx.doi.org/10.1093/cid/ciy585] [PMID: 30215672]
[98]
Rosenthal P, Schwarz KB, Gonzalez-Peralta RP, et al. Sofosbuvir and ribavirin therapy for children aged 3 to <12 Years with hepatitis C virus genotype 2 or 3 infection. Hepatology 2020; 71(1): 31-43.
[http://dx.doi.org/10.1002/hep.30821] [PMID: 31222783]
[99]
Jonas MM, Rhee S, Kelly DA, et al. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in children with chronic HCV: Part 2 of the DORA study. Hepatology 2021; 74(1): 19-27.
[http://dx.doi.org/10.1002/hep.31841] [PMID: 33811356]
[100]
World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. 2016.
[101]
Rupp C, Hippchen T, Neuberger M, et al. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus. World J Gastroenterol 2018; 24(12): 1353-60.
[http://dx.doi.org/10.3748/wjg.v24.i12.1353] [PMID: 29599610]
[102]
Schwarz KB, Rosenthal P, Murray KF, et al. Ledipasvir-Sofosbuvir for 12 weeks in children 3 to <6 Years old with chronic hepatitis C. Hepatology 2020; 71(2): 422-30.
[http://dx.doi.org/10.1002/hep.30830] [PMID: 31220349]
[103]
Nwaohiri A, Schillie S, Bulterys M, Kourtis AP, Hepatitis C. Hepatitis C virus infection in children: How do we prevent it and how do we treat it? Expert Rev Anti Infect Ther 2018; 16(9): 689-94.
[http://dx.doi.org/10.1080/14787210.2018.1509707] [PMID: 30091654]
[104]
Commissioner O. of the. FDA approves two hepatitis C drugs for pediatric patients. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-two-hepatitis-c-drugs-pediatric-patients (accessed Feb 28, 2021).
[105]
Squires JE, Balistreri WF. Treatment of hepatitis C: A new paradigm toward viral eradication. J Pediatr 2020; 221: 12-22.e1.
[http://dx.doi.org/10.1016/j.jpeds.2020.02.082] [PMID: 32446469]
[106]
Commissioner O. of the. FDA approves first treatment for all genotypes of hepatitis C in pediatric patients. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-all-genotypes-hepatitis-c-pediatric-patients (accessed Feb 28, 2021).
[107]
Drugs@FDA: FDA-approved drugs-sofosbuvir. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212480 (accessed Sep 9, 2021).
[108]
Drugs@FDA: FDA-approved drugs-sofosbuvir/velpatasvir. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214187 (accessed Sep 9, 2021).
[109]
Commissioner O. of the. FDA approves new treatment for pediatric patients with any strain of hepatitis C. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-pediatric-patients-any-strain-hepatitis-c (accessed Feb 28, 2021).
[110]
Hepatitis C and dietary supplements. Available from: https://wwwnccih.nih.gov/health/hepatitis-c-and-dietary-supplements (accessed Feb 28, 2021).
[111]
Balistreri WF, Murray KF, Rosenthal P, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology 2017; 66(2): 371-8.
[http://dx.doi.org/10.1002/hep.28995] [PMID: 27997679]
[112]
Jonas M, Romero R, Sokal E. Safety and efficacy of sofosbuvir/velpatasvir in pediatric patients 6 to <18 years old with chronic hepatitis C infection. The Liver Meeting, Boston, Massachusetts. 2019.
[113]
Jonas MM, Squires RH, Rhee SM, et al. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in adolescents with chronic hepatitis C virus: Part 1 of the DORA study. Hepatology 2020; 71(2): 456-62.
[http://dx.doi.org/10.1002/hep.30840] [PMID: 31254392]
[114]
HCV testing and linkage to care | HCV guidance. Available from: https://www.hcvguidelines.org/evaluate/testing-and-linkage (accessed Feb 28, 2021).
[115]
Dugan E, Blach S, Biondi M, et al. Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study. Lancet Gastroenterol Hepatol 2021; 6(3): 169-84.
[http://dx.doi.org/10.1016/S2468-1253(20)30359-9] [PMID: 33515496]
[116]
Chappell CA, Scarsi KK, Kirby BJ, et al. Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: A phase 1 pharmacokinetic study. Lancet Microbe 2020; 1(5): e200-8.
[http://dx.doi.org/10.1016/S2666-5247(20)30062-8] [PMID: 32939459]
[117]
Dar GA, Yattoo GN, Gulzar GM, Sodhi JS, Gorka S, Laway MA. Treatment of chronic hepatitis C genotype 3 with ledipasvir and sofosbuvir: An observational study. J Clin Exp Hepatol 2021; 11(2): 227-31.
[http://dx.doi.org/10.1016/j.jceh.2020.06.011] [PMID: 33746448]
[118]
Drugs@FDA: FDA-approved drugs-ribavirin. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020903 (accessed Sep 20, 2021).
[119]
van Santen DK, Boyd A, Matser A, et al. The effect of needle and syringe program and opioid agonist therapy on the risk of HIV, hepatitis B and C virus infection for people who inject drugs in Amsterdam, the Netherlands: Findings from an emulated target trial. Addiction 2021; 116(11): 3115-26.
[http://dx.doi.org/10.1111/add.15503] [PMID: 33788326]
[120]
Des Jarlais DC, Nugent A, Solberg A, Feelemyer J, Mermin J, Holtzman D. Syringe service programs for persons who inject drugs in urban, suburban, and rural areas - United States, 2013. MMWR Morb Mortal Wkly Rep 2015; 64(48): 1337-41.
[http://dx.doi.org/10.15585/mmwr.mm6448a3] [PMID: 26655918]
[121]
Eckhardt BJ, Scherer M, Winkelstein E, Marks K, Edlin BR, Hepatitis C. Hepatitis C treatment outcomes for people who inject drugs treated in an accessible care program located at a syringe service program. Open Forum Infect Dis 2018; 5(4): ofy048.
[http://dx.doi.org/10.1093/ofid/ofy048] [PMID: 29644246]
[122]
Centers for Disease Control and Prevention (CDC). Syringe exchange programs-United States, 2008. MMWR Morb Mortal Wkly Rep 2010; 59(45): 1488-91.
[PMID: 21085091]
[123]
Reilley B, Leston J, Hariri S, et al. Birth cohort testing for hepatitis C virus - indian health service 2012-2015. MMWR Morb Mortal Wkly Rep 2016; 65(18): 467-9.
[http://dx.doi.org/10.15585/mmwr.mm6518a3] [PMID: 27171026]
[124]
Page K, Melia MT, Veenhuis RT, et al. Randomized trial of a vaccine regimen to prevent chronic HCV infection. N Engl J Med 2021; 384(6): 541-9.
[http://dx.doi.org/10.1056/NEJMoa2023345] [PMID: 33567193]
[125]
Foster MA, Grigg C, Hagon J, et al. Notes from the field: Investigation of hepatitis C virus transmission associated with injection therapy for chronic pain - California, 2015. MMWR Morb Mortal Wkly Rep 2016; 65(21): 547-9.
[http://dx.doi.org/10.15585/mmwr/mm6521a4] [PMID: 27254396]
[126]
Centers for Disease Control and Prevention (CDC). Establishment of a viral hepatitis surveillance system--Pakistan, 2009-2011. MMWR Morb Mortal Wkly Rep 2011; 60(40): 1385-90.
[PMID: 21993343]
[127]
Homer CS, Oats J, Middleton P, Ramson J, Diplock S. Updated clinical practice guidelines on pregnancy care. Med J Aust 2018; 209(9): 409-12.
[http://dx.doi.org/10.5694/mja18.00286] [PMID: 30376663]
[128]
Checa Cabot CA, Stoszek SK, Quarleri J, et al. NICHD International Site Development Initiative Perinatal/Longitudinal Study in Latin American Countries Study Group. Mother-to-child transmission of hepatitis C virus (HCV) among HIV/HCV-coinfected women. J Pediatric Infect Dis Soc 2013; 2(2): 126-35.
[http://dx.doi.org/10.1093/jpids/pis091] [PMID: 26199724]
[129]
Ghamar Chehreh ME, Tabatabaei SV, Khazanehdari S, Alavian SM. Effect of cesarean section on the risk of perinatal transmission of hepatitis C virus from HCV-RNA+/HIV- mothers: A meta-analysis. Arch Gynecol Obstet 2011; 283(2): 255-60.
[http://dx.doi.org/10.1007/s00404-010-1588-9] [PMID: 20652289]
[130]
McMenamin MB, Jackson AD, Lambert J, et al. Obstetric management of hepatitis C-positive mothers: Analysis of vertical transmission in 559 mother-infant pairs. Am J Obstet Gynecol 2008; 199(3): 315.e1-5.
[http://dx.doi.org/10.1016/j.ajog.2008.05.021] [PMID: 18771997]
[131]
European Paediatric Hepatitis C Virus Network. A significant sex--but not elective cesarean section-effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis 2005; 192(11): 1872-9.
[http://dx.doi.org/10.1086/497695] [PMID: 16267757]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy